{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:18:30Z","timestamp":1792919910972,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,4,1]]},"abstract":"<jats:p>Lymphoblastic lymphoma (LBL) is a rare, clinically aggressive neoplasm of the young that frequently involves the bone marrow (BM) and\/or central nervous system. Because LBL is similar to acute lymphoblastic leukemia, some centers prefer allogeneic hematopoietic stem cell (SC) transplantation to autologous SC transplantation. We retrospectively analyzed outcomes for patients who underwent autologous (auto, n\u2009=\u2009128) or HLA-identical sibling (allo, n\u2009=\u200976) SC transplantations from 1989 to 1998 and were reported to International Bone Marrow Transplant Registry (IBMTR) or Autologous Blood and Marrow Transplant Registry (ABMTR). Allo stem cell transplant (SCT) recipients had higher treatment-related mortality (TRM) at 6 months (18% versus 3%, P\u2009=\u2009.002), and this disadvantage persisted at 1 and 5 years. Early relapse rates after alloSC transplantation and autoSC transplantation were similar, but significantly lower relapse rates were observed in alloSCT recipients at 1 and 5 years (32% versus 46%, P\u2009=\u2009.05; and 34% versus 56%,P\u2009=\u2009.004, respectively). No differences were noted in lymphoma-free survival rates between alloSC transplantations and autoSC transplantations (5-year rates 36% versus 39%,P\u2009=\u2009.82). AutoSCT recipients had higher overall survival at 6 months (75% versus 59%, P\u2009=\u2009.01), but survival did not significantly differ between the 2 groups at 1 and 5 years (60% versus 49%, P\u2009=\u2009.09; 44% versus 39%,P\u2009=\u2009.47, respectively). Multivariate analyses to account for confounding factors confirmed these results. Independent of SCT type, BM involvement at the time of transplantation and disease status more advanced than first complete remission were associated with inferior outcomes. In summary, alloSC transplantation for LBL is associated with fewer relapses than with autoSC transplantation, but higher TRM offsets any potential survival benefit.<\/jats:p>","DOI":"10.1182\/blood-2002-05-1483","type":"journal-article","created":{"date-parts":[[2003,3,17]],"date-time":"2003-03-17T15:22:55Z","timestamp":1047914575000},"page":"2476-2482","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":132,"title":["A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma"],"prefix":"10.1182","volume":"101","author":[{"given":"John E.","family":"Levine","sequence":"first","affiliation":[{"name":"From the University of Michigan Medical Center, Ann Arbor; Children's Hospital Medical Center, Cincinnati, OH; International Bone Marrow Transplant Registry\/Autologous Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee; University of Nebraska Medical Center, Omaha; Case Western Reserve University, Cleveland, OH; University of Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Harris","sequence":"additional","affiliation":[{"name":"From the University of Michigan Medical Center, Ann Arbor; Children's Hospital Medical Center, Cincinnati, OH; International Bone Marrow Transplant Registry\/Autologous Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee; University of Nebraska Medical Center, Omaha; Case Western Reserve University, Cleveland, OH; University of Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Fausto R.","family":"Loberiza","sequence":"additional","affiliation":[{"name":"From the University of Michigan Medical Center, Ann Arbor; Children's Hospital Medical Center, Cincinnati, OH; International Bone Marrow Transplant Registry\/Autologous Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee; University of Nebraska Medical Center, Omaha; Case Western Reserve University, Cleveland, OH; University of Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[{"name":"From the University of Michigan Medical Center, Ann Arbor; Children's Hospital Medical Center, Cincinnati, OH; International Bone Marrow Transplant Registry\/Autologous Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee; University of Nebraska Medical Center, Omaha; Case Western Reserve University, Cleveland, OH; University of Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"From the University of Michigan Medical Center, Ann Arbor; Children's Hospital Medical Center, Cincinnati, OH; International Bone Marrow Transplant Registry\/Autologous Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee; University of Nebraska Medical Center, Omaha; Case Western Reserve University, Cleveland, OH; University of Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Besien","sequence":"additional","affiliation":[{"name":"From the University of Michigan Medical Center, Ann Arbor; Children's Hospital Medical Center, Cincinnati, OH; International Bone Marrow Transplant Registry\/Autologous Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee; University of Nebraska Medical Center, Omaha; Case Western Reserve University, Cleveland, OH; University of Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"From the University of Michigan Medical Center, Ann Arbor; Children's Hospital Medical Center, Cincinnati, OH; International Bone Marrow Transplant Registry\/Autologous Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee; University of Nebraska Medical Center, Omaha; Case Western Reserve University, Cleveland, OH; University of Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"From the University of Michigan Medical Center, Ann Arbor; Children's Hospital Medical Center, Cincinnati, OH; International Bone Marrow Transplant Registry\/Autologous Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee; University of Nebraska Medical Center, Omaha; Case Western Reserve University, Cleveland, OH; University of Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111822324794500_B1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes.","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol."},{"key":"2019111822324794500_B2","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/1097-0142(19811201)48:11<2347::AID-CNCR2820481102>3.0.CO;2-X","article-title":"Lymphoblastic lymphoma: a clinicopathologic study of 95 patients.","volume":"48","author":"Nathwani","year":"1981","journal-title":"Cancer."},{"key":"2019111822324794500_B3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/blood.V67.2.474.474","article-title":"Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia.","volume":"67","author":"Weiss","year":"1986","journal-title":"Blood."},{"key":"2019111822324794500_B4","first-page":"4486","article-title":"Diversity of immunological phenotypes of lymphoblastic lymphoma.","volume":"43","author":"Cossman","year":"1983","journal-title":"Cancer Res."},{"key":"2019111822324794500_B5","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1200\/JCO.1986.4.11.1628","article-title":"Treatment of lymphoblastic lymphoma in adults.","volume":"4","author":"Coleman","year":"1986","journal-title":"J Clin Oncol."},{"key":"2019111822324794500_B6","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","article-title":"Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.","volume":"99","author":"Hoelzer","year":"2002","journal-title":"Blood."},{"key":"2019111822324794500_B7","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1995.13.6.1368","article-title":"Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.","volume":"3","author":"Tubergen","year":"1995","journal-title":"J Clin Oncol."},{"key":"2019111822324794500_B8","first-page":"416","article-title":"Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.","volume":"95","author":"Reiter","year":"2000","journal-title":"Blood."},{"key":"2019111822324794500_B9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM199304083281409","article-title":"Drug therapy: treatment of non-Hodgkin's lymphoma.","volume":"328","author":"Armitage","year":"1993","journal-title":"N Engl J Med."},{"key":"2019111822324794500_B10","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2001.19.9.2390","article-title":"Outcomes of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy and transplantation: Childrens Cancer Group study CCG-5912.","volume":"19","author":"Kobrinsky","year":"2001","journal-title":"J Clin Oncol."},{"key":"2019111822324794500_B11","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1200\/JCO.1993.11.6.1024","article-title":"Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report from the Childrens Cancer Group.","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol."},{"key":"2019111822324794500_B12","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2001.19.11.2927","article-title":"High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation\/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.","volume":"19","author":"Sweetenham","year":"2001","journal-title":"J Clin Oncol."},{"key":"2019111822324794500_B13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1023\/A:1008202808144","article-title":"Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center.","volume":"9","author":"Bouabdallah","year":"1998","journal-title":"Ann Oncol."},{"key":"2019111822324794500_B14","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.1992.10.11.1690","article-title":"Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data.","volume":"10","author":"Chopra","year":"1992","journal-title":"J Clin Oncol."},{"key":"2019111822324794500_B15","first-page":"767","article-title":"Role of allogeneic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma in first remission.","volume":"14","author":"De Witte","year":"1994","journal-title":"Bone Marrow Transplant."},{"key":"2019111822324794500_B16","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.1994.12.7.1358","article-title":"High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation.","volume":"12","author":"Sweetenham","year":"1994","journal-title":"J Clin Oncol."},{"key":"2019111822324794500_B17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/JCO.1986.4.4.480","article-title":"High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma.","volume":"4","author":"Phillips","year":"1986","journal-title":"J Clin Oncol."},{"key":"2019111822324794500_B18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2141.1992.tb06423.x","article-title":"Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children's Cancer Study Group (UKCCSG) protocol 8503.","volume":"82","author":"Eden","year":"1992","journal-title":"Br J Haematol."},{"key":"2019111822324794500_B19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(97)89488-0","article-title":"Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity, and survival depend on disease histology.","volume":"100","author":"van Besien","year":"1996","journal-title":"Am J Med."},{"key":"2019111822324794500_B20","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect.","volume":"19","author":"Van Besien","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"2019111822324794500_B21","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood."},{"key":"2019111822324794500_B22","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)11135-2","article-title":"Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation.","volume":"353","author":"Sykes","year":"1999","journal-title":"Lancet."},{"key":"2019111822324794500_B23"},{"key":"2019111822324794500_B24","first-page":"1","volume":"108","author":"Graves","year":"1991","journal-title":"Detailed diagnoses and procedures, National Hospital Discharge Survey, 1989. Vital & Health Statistics, Series 13: Data from the National Health Survey."},{"key":"2019111822324794500_B25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM199703273361301","article-title":"Solid cancers after bone marrow transplantation.","volume":"336","author":"Curtis","year":"1997","journal-title":"N Engl J Med."},{"key":"2019111822324794500_B26","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1056\/NEJM199410203311606","article-title":"Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries.","volume":"331","author":"Silberman","year":"1994","journal-title":"N Engl J Med."},{"key":"2019111822324794500_B27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med."},{"key":"2019111822324794500_B28","first-page":"334","volume-title":"Survival Analysis: Techniques for Censored and Truncated Data.","author":"Klein","year":"1996"},{"key":"2019111822324794500_B29","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#","article-title":"Testing for center effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests.","volume":"18","author":"Andersen","year":"1999","journal-title":"Stat Med."},{"key":"2019111822324794500_B30","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation.","volume":"88","author":"Bjorkstrand","year":"1996","journal-title":"Blood."},{"key":"2019111822324794500_B31","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease.","volume":"14","author":"Milpied","year":"1996","journal-title":"J Clin Oncol."},{"key":"2019111822324794500_B32","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199812033392301","article-title":"Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.","volume":"339","author":"Cassileth","year":"1998","journal-title":"N Engl J Med."},{"key":"2019111822324794500_B33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/00000421-199710000-00005","article-title":"Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.","volume":"20","author":"Varterasian","year":"1997","journal-title":"Am J Clin Oncol."},{"key":"2019111822324794500_B34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation.","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood."},{"key":"2019111822324794500_B35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood.V94.2.825","article-title":"Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.","volume":"94","author":"Krijanovski","year":"1999","journal-title":"Blood."},{"key":"2019111822324794500_B36","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI12156","article-title":"LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.","volume":"107","author":"Cooke","year":"2001","journal-title":"J Clin Invest."},{"key":"2019111822324794500_B37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood."},{"key":"2019111822324794500_B38","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2002-02-0400","article-title":"Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.","volume":"100","author":"Martino","year":"2002","journal-title":"Blood."},{"key":"2019111822324794500_B39","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood."},{"key":"2019111822324794500_B40","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","article-title":"Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.","volume":"18","author":"Carella","year":"2000","journal-title":"J Clin Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/7\/2476\/1272665\/h80703002476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/7\/2476\/1272665\/h80703002476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:33:07Z","timestamp":1574116387000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/7\/2476\/106688\/A-comparison-of-allogeneic-and-autologous-bone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,1]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-05-1483","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4,1]]}}}